Yarlagadda S. Babu net worth and biography

Yarlagadda Babu Biography and Net Worth

Dr. Yarlagadda S. Babu Ph.D. serves as Senior Vice President - Drug Discovery of the Company. Dr. Babu joined BioCryst in 1988 and was BioCryst’s first full-time employee. Dr. Babu has served as the Company’s Vice President — Drug Discovery since 1992. In October of 2013, Dr. Babu’s title was changed to Senior Vice President of Drug Discovery. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham (“UAB”). Dr. Babu obtained his Ph.D. from the Indian Institute of Science, Bangalore and spent three years in the Laboratory of Molecular Biophysics at the University of Oxford, U.K. before joining UAB. He has over 70 publications in peer-reviewed journals, and a number of issued and pending patents to his credit.

What is Yarlagadda S. Babu's net worth?: The estimated net worth of Yarlagadda S. Babu is at least $2.10 million as of November 14th, 2022. Dr. Babu owns 298,541 shares of BioCryst Pharmaceuticals stock worth more than $2,098,743 as of November 17th. This net worth estimate does not reflect any other investments that Dr. Babu may own. Learn More about Yarlagadda S. Babu's net worth.
How do I contact Yarlagadda S. Babu?: The corporate mailing address for Dr. Babu and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]. Learn More on Yarlagadda S. Babu's contact information.
Has Yarlagadda S. Babu been buying or selling shares of BioCryst Pharmaceuticals?: Yarlagadda S. Babu has not been actively trading shares of BioCryst Pharmaceuticals during the last quarter. Most recently, Yarlagadda S. Babu sold 31,515 shares of the business's stock in a transaction on Monday, November 14th. The shares were sold at an average price of $13.88, for a transaction totalling $437,428.20. Following the completion of the sale, the insider now directly owns 298,541 shares of the company's stock, valued at $4,143,749.08. Learn More on Yarlagadda S. Babu's trading history.
Who are BioCryst Pharmaceuticals' active insiders?: BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Nancy Hutson (Director), Vincent Milano (Director), William Sheridan (Insider), and Jon Stonehouse (CEO). Learn More on BioCryst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of BioCryst Pharmaceuticals?: During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.
Information on this page was last updated on 6/24/2024.

Yarlagadda S. Babu Insider Trading History at BioCryst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2022	Sell	31,515	$13.88	$437,428.20	298,541
12/7/2021	Sell	30,100	$12.20	$367,220.00
8/25/2016	Sell	30,000	$4.06	$121,800.00	111,428
3/19/2015	Sell	12,105	$10.16	$122,986.80
3/5/2015	Sell	37,400	$10.59	$396,066.00
3/4/2015	Sell	10,495	$10.50	$110,197.50

Yarlagadda S. Babu Buying and Selling Activity at BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Today's Range

Now: $7.03

$6.93

$7.52

50 Day Range

MA: $7.70

$7.03

$8.43

2 Week Range

Now: $7.03

$4.03

$8.88

Volume

2,831,577 shs

Average Volume

2,457,807 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

This company will win the AI race

From Porter & Company | Ad

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.